PSA-density, DRE, and PI-RADS 5: potential surrogates for omitting biopsy?
Fabian FalkenbachFrancesca AmbrosiniMykyta KachanovGernot OrtnerTobias MaurerDaniel KöhlerDirk BeyersdorffMarkus GraefenLars BudäusPublished in: World journal of urology (2024)
In PI-RADS 5 patients, PSA-D and cT-stage emerged as strong predictors of csPCA at biopsy. Moreover, when adding the threshold of PSA-D > 0,5 ng/ml/cc, all PI-RADS 5 patients were diagnosed with csPCA. Therefore, straight treatment for PCA can be considered, especially if risk-factors for biopsy-related complications such as obligatory dual platelet inhibition are present.